Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jose Baselga

Showing results (21-30 of 126) with videos related to

Pageof 13
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 4, 2005
A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancerKathy D Miller, Jose Manuel Trigo, Catherine Wheeler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 10, 2003
ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cellsJudit Anido, Pablo Matar, Joan Albanell, et al.
Cancer|September 20, 2006
Phosphorylated 4E binding protein 1: a hallmark of cell signaling that correlates with survival in ovarian cancerJosep Castellvi, Angel Garcia, Federico Rojo, et al.
Cancer Research|February 21, 2006
Reduction of cytosolic p27(Kip1) inhibits cancer cell motility, survival, and tumorigenicityFrederick Y Wu, Shizhen Emily Wang, Melinda E Sanders, et al.
Nature Medicine|September 24, 2002
PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localizationIncheol Shin, F Michael Yakes, Federico Rojo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 4, 2007
4E-binding protein 1, a cell signaling hallmark in breast cancer that correlates with pathologic grade and prognosisFederico Rojo, Laura Najera, José Lirola, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 15, 2024
Editor's Note: 4E-Binding Protein 1, a Cell Signaling Hallmark in Breast Cancer That Correlates with Pathologic Grade and PrognosisFederico Rojo, Laura Najera, José Lirola, et al.
Cancer Cell|January 11, 2011
AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activitySarat Chandarlapaty, Ayana Sawai, Maurizio Scaltriti, et al.
Biologics : Targets & Therapy|August 27, 2009
Analysis and variability of TGFbeta measurements in cancer patients with skeletal metastasesPeter J O'Brien, Rajeev Ramanathan, Jonathan M Yingling, et al.
Science Translational Medicine|April 24, 2015
An implantable microdevice to perform high-throughput in vivo drug sensitivity testing in tumorsOliver Jonas, Heather M Landry, Jason E Fuller, et al.
Pageof 13

Showing results (21-30 of 126) with videos related to

Sort By:
Pageof 13
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 4, 2005
A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancerKathy D Miller, Jose Manuel Trigo, Catherine Wheeler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 10, 2003
ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cellsJudit Anido, Pablo Matar, Joan Albanell, et al.
Cancer|September 20, 2006
Phosphorylated 4E binding protein 1: a hallmark of cell signaling that correlates with survival in ovarian cancerJosep Castellvi, Angel Garcia, Federico Rojo, et al.
Cancer Research|February 21, 2006
Reduction of cytosolic p27(Kip1) inhibits cancer cell motility, survival, and tumorigenicityFrederick Y Wu, Shizhen Emily Wang, Melinda E Sanders, et al.
Nature Medicine|September 24, 2002
PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localizationIncheol Shin, F Michael Yakes, Federico Rojo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 4, 2007
4E-binding protein 1, a cell signaling hallmark in breast cancer that correlates with pathologic grade and prognosisFederico Rojo, Laura Najera, José Lirola, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 15, 2024
Editor's Note: 4E-Binding Protein 1, a Cell Signaling Hallmark in Breast Cancer That Correlates with Pathologic Grade and PrognosisFederico Rojo, Laura Najera, José Lirola, et al.
Cancer Cell|January 11, 2011
AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activitySarat Chandarlapaty, Ayana Sawai, Maurizio Scaltriti, et al.
Biologics : Targets & Therapy|August 27, 2009
Analysis and variability of TGFbeta measurements in cancer patients with skeletal metastasesPeter J O'Brien, Rajeev Ramanathan, Jonathan M Yingling, et al.
Science Translational Medicine|April 24, 2015
An implantable microdevice to perform high-throughput in vivo drug sensitivity testing in tumorsOliver Jonas, Heather M Landry, Jason E Fuller, et al.
Pageof 13